GTHX - G1 Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

G1 Therapeutics, Inc.

79 T.W. Alexander Drive
Suite 100 4501 Research Commons
Research Triangle Park, NC 27709
United States
919-213-9835
http://www.g1therapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees84

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark A. VellecaCEO, Pres & Director870.12k3.08M1964
Mr. James Stillman HansonGen. Counsel402.38kN/A1972
Mr. Terry L. MurdockSr. VP of Devel. Operations541.59k606.34k1960
Mr. John DemareeChief Commercial Officer359.35kN/A1967
Ms. Jennifer K. MosesChief Financial OfficerN/AN/A1975
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Corporate Governance

G1 Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.